http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 02 Sep 2026 06:54:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27015425.html <p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $455.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).</p><p>The analyst commented: "On August 28, primary results for Ionis Pharmaceuticals' and AstraZeneca's antisense oligonucleotide (ASO) eplontersen (WAINUA) were presented in a Hot Line session at the European Society of Cardiology (ESC) Congress 2026, held August 28-31 in Munich, and published simultaneously in the New England Journal of Medicine; a prespecified stabilizer-subgroup analysis followed on August 30 and was published in Nature Medicine. The composite of cardiovascular (CV) death and recurrent CV events through Week 140 produced 381 events in 210 of 715 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27015425.html Wed, 02 Sep 2026 06:54:58 -0400 ALNY http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27002044.html <p>Stifel analyst Paul Matteis reiterated a Buy rating and $318.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).</p><p>The analyst commented, "Coming out of ESC, there is a case that TRITON-CM could be in okay shape to still succeed, assuming ALNY is enriching the trial for NAC1, milder TTR-CM patients as they are alluding to. In the NAC1 (earlystage) population for CARDIO-TTRansform, eplontersen beat placebo with an HR on the primary outcome of 0.63 (CI 0.47-0.84), and notably, the NAC1 population was comprised of ~60% of patients on background tafamidis. This is a notable datapoint and suggests that there was probably benefit http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27002044.html Mon, 31 Aug 2026 09:20:05 -0400 ALNY http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27001949.html <p>Truist Securities analyst Danielle Brill reiterated a Buy rating and $315.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).</p><p>The analyst commented: "Readthroughs to ALNY from the CARDIOTTRansform Data; This morning, data from the TTR silencer eplontersen CARDIO-TTRansform trial were presented at ESC. Following the surprise trial failure, investors have been focused on better understanding the potential implications for ALNY’s Amvuttra’s commercial outlook as well as its next-generation nucresiran which is currently being evaluated in the pivotal TRITONCM trial. In short, several questions remain to fully understand how the TTR-CM treatment landscape may evolve as a result of CARDIO-TTRansform’s findings, however, we http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27001949.html Mon, 31 Aug 2026 09:05:39 -0400 ALNY http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27001921.html <p>TD Cowen analyst Ritu Baral reiterated a Buy rating and $482.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).</p><p>The analyst commented: "HELIOS-B Taf Subgroup Analysis, More Silencing Drives Better Outcomes; ESC '26 data supports the hypothesis that TTR silencing remains a highly effective strategy in TTR-CM, with benefit likely driven by 3 factors: TTR KD levels, tx earlier in the disease course, and EP selection. All three factors emerge as potential differentiators for nucresiran in TRITONCM (including projected TTR KD of ~95% vs ~87% w/ Amvuttra & 75% w/ Wainua) supporting the study's high PoS."</p><p>For an analyst ratings summary and ratings http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27001921.html Mon, 31 Aug 2026 09:03:08 -0400 ALNY http://www.streetinsider.com/Analyst+Comments/BMO+Capital+on+Alnylam+Pharmaceuticals+%28ALNY%29%3A+%27Strong+ATTR+Outlook+With+Limited+Readthrough+From+Eplontersen%27/27001751.html <p>BMO Capital analyst David Lebowitz reiterated an Outperform rating and $318.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).</p><p>The analyst commented: "Strong ATTR Outlook With Limited Readthrough From Eplontersen; While detailed eplontersen data dominated the ATTR-CM discussion at ESC, Alnylam presented post hoc and real-world analyses showing consistent Amvuttra efficacy across cardiovascular and systemic manifestations and key patient subgroups. Management’s ESC investor event also highlighted commercial dynamics supporting continued first-line leadership and sales growth, as well as TRITON-CM design features intended to maximize its probability of success. While we continue to see upside from Alnylam’s ex-ATTR pipeline, Amvuttra and nucresiran are http://www.streetinsider.com/Analyst+Comments/BMO+Capital+on+Alnylam+Pharmaceuticals+%28ALNY%29%3A+%27Strong+ATTR+Outlook+With+Limited+Readthrough+From+Eplontersen%27/27001751.html Mon, 31 Aug 2026 08:57:06 -0400 ALNY http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27000991.html <p>Canaccord analyst Whitney Ijem reiterated a Buy rating and $429.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).</p><p>The analyst commented: "We are currently attending the European Society of Cardiology Congress (ESC; August 28–31, Munich), where more detailed CARDIO-TTRansform data were presented this morning; full results were also published in NEJM. We attended the data presentation (standing room only, no time for Q&A) as well as several subsequent TTR sessions, including an “Ask the Trialist” session with Dr. Mathew Maurer (Columbia). Our more detailed initial thoughts and takeaways from that session are below. Bottom line: the incremental data detail supports what we http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Alnylam+Pharmaceuticals+%28ALNY%29/27000991.html Mon, 31 Aug 2026 07:10:56 -0400 ALNY http://www.streetinsider.com/Corporate+News/Alnylam+presents+vutrisiran+and+zilebesiran+data+at+ESC+2026/27000240.html <p>Alnylam Pharmaceuticals (Nasdaq: ALNY) presented new clinical data at the European Society of Cardiology Congress 2026, including a prespecified subgroup analysis of the HELIOS-B Phase 3 trial evaluating vutrisiran in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM).</p><p>The analysis, simultaneously published in the <em>Journal of the American College of Cardiology</em>, examined treatment effects in 654 randomized patients, of whom 259 (40%) were receiving tafamidis at baseline. Results showed consistent effects on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33–36 months regardless of baseline tafamidis use. Functional capacity, measured by the Six-Minute Walk Test, was preserved with vutrisiran http://www.streetinsider.com/Corporate+News/Alnylam+presents+vutrisiran+and+zilebesiran+data+at+ESC+2026/27000240.html Mon, 31 Aug 2026 06:04:19 -0400 ALNY http://www.streetinsider.com/FDA/Alnylam+presents+vutrisiran+and+zilebesiran+data+at+ESC+2026/27000240.html <p>Alnylam Pharmaceuticals (Nasdaq: ALNY) presented new clinical data at the European Society of Cardiology Congress 2026, including a prespecified subgroup analysis of the HELIOS-B Phase 3 trial evaluating vutrisiran in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM).</p><p>The analysis, simultaneously published in the <em>Journal of the American College of Cardiology</em>, examined treatment effects in 654 randomized patients, of whom 259 (40%) were receiving tafamidis at baseline. Results showed consistent effects on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33–36 months regardless of baseline tafamidis use. Functional capacity, measured by the Six-Minute Walk Test, was preserved with vutrisiran http://www.streetinsider.com/FDA/Alnylam+presents+vutrisiran+and+zilebesiran+data+at+ESC+2026/27000240.html Mon, 31 Aug 2026 06:04:19 -0400 ALNY http://www.streetinsider.com/Press+Releases/Alnylam+Presents+New+Data+at+ESC+Congress+2026+Reinforcing+Strength+in+RNAi-Powered+TTR+Silencing+Across+ATTR-CM+Patient+Populations+and+Treatment+Settings/26999691.html <p class="bwalignc"> <i>–</i> <i>Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline –</i> </p><p class="bwalignc"> <i>–</i> <i>Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM –</i> </p><p class="bwalignc"> <i>–</i> <i>Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes –</i> </p><p class="bwalignc"> <i>–</i> <i>New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control –</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54596166&amp;newsitemid=20260829551848&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=387567ee320704ee12426925a3729c83" shape="rect">Alnylam http://www.streetinsider.com/Press+Releases/Alnylam+Presents+New+Data+at+ESC+Congress+2026+Reinforcing+Strength+in+RNAi-Powered+TTR+Silencing+Across+ATTR-CM+Patient+Populations+and+Treatment+Settings/26999691.html Sun, 30 Aug 2026 08:23:00 -0400 ALNY O.00980119 http://www.streetinsider.com/Press+Releases/Alnylam+Presents+New+Data+at+ESC+Congress+2026+Reinforcing+Strength+in+RNAi-Powered+TTR+Silencing+Across+ATTR-CM+Patient+Populations+and+Treatment+Settings/26999691.html <p class="bwalignc"> <i>–</i> <i>Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline –</i> </p><p class="bwalignc"> <i>–</i> <i>Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM –</i> </p><p class="bwalignc"> <i>–</i> <i>Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes –</i> </p><p class="bwalignc"> <i>–</i> <i>New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control –</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54596166&amp;newsitemid=20260829551848&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=387567ee320704ee12426925a3729c83" shape="rect">Alnylam http://www.streetinsider.com/Press+Releases/Alnylam+Presents+New+Data+at+ESC+Congress+2026+Reinforcing+Strength+in+RNAi-Powered+TTR+Silencing+Across+ATTR-CM+Patient+Populations+and+Treatment+Settings/26999691.html Sun, 30 Aug 2026 08:23:00 -0400 ALNY O.00980119 http://www.streetinsider.com/Business+Wire/Alnylam+Presents+New+Data+at+ESC+Congress+2026+Reinforcing+Strength+in+RNAi-Powered+TTR+Silencing+Across+ATTR-CM+Patient+Populations+and+Treatment+Settings/26999691.html <p class="bwalignc"> <i>–</i> <i>Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline –</i> </p><p class="bwalignc"> <i>–</i> <i>Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM –</i> </p><p class="bwalignc"> <i>–</i> <i>Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes –</i> </p><p class="bwalignc"> <i>–</i> <i>New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control –</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54596166&amp;newsitemid=20260829551848&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=387567ee320704ee12426925a3729c83" shape="rect">Alnylam http://www.streetinsider.com/Business+Wire/Alnylam+Presents+New+Data+at+ESC+Congress+2026+Reinforcing+Strength+in+RNAi-Powered+TTR+Silencing+Across+ATTR-CM+Patient+Populations+and+Treatment+Settings/26999691.html Sun, 30 Aug 2026 08:23:00 -0400 ALNY O.00980119